Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for Q91Y11

Entry ID Method Resolution Chain Position Source
AF-Q91Y11-F1 Predicted AlphaFoldDB

61 variants for Q91Y11

Variant ID(s) Position Change Description Diseaes Association Provenance
rs226711998 12 T>I No EVA
rs240217229 41 A>T No EVA
rs3408476992 45 L>I No EVA
rs245239214 56 V>A No EVA
rs225568090 56 V>L No EVA
rs24886830 56 V>S No EVA
rs3389454869 64 S>Y No EVA
rs3408364733 65 V>G No EVA
rs3407778201 66 P>T No EVA
rs3389510790 84 L>M No EVA
rs245370691 87 A>T No EVA
rs24886834 97 V>A No EVA
rs3407451770 106 E>K No EVA
rs3407379626 111 N>K No EVA
rs24886837 129 N>S No EVA
rs24886840 188 S>C No EVA
rs13498863 288 K>Q No EVA
rs261328442 317 S>L No EVA
rs3389488576 339 D>H No EVA
rs3389510802 351 D>V No EVA
rs250178599 365 T>S No EVA
rs3389405617 376 N>I No EVA
rs229590138 396 G>S No EVA
rs31785838 396 G>V No EVA
rs24886846 399 I>V No EVA
rs3389454925 425 F>V No EVA
rs3389405540 427 L>S No EVA
rs24886850 449 A>T No EVA
rs3408335884 466 W>* No EVA
rs3408432236 466 W>S No EVA
rs579051558 468 T>M No EVA
rs3408476974 469 A>D No EVA
rs3408331460 472 S>A No EVA
rs3408432269 474 E>A No EVA
rs3389496207 475 V>M No EVA
rs3389444223 483 P>H No EVA
rs13489671 487 H>Q No EVA
rs582214236 488 P>S No EVA
rs24886854 502 V>A No EVA
rs24886854 502 V>D No EVA
rs578800685 508 L>S No EVA
rs585290944 510 V>M No EVA
rs3389475979 514 A>V No EVA
rs3389462031 540 V>M No EVA
rs3389454914 546 K>T No EVA
rs3389495841 589 N>I No EVA
rs24886861 610 L>F No EVA
rs3408601849 630 D>E No EVA
rs3389454885 675 R>G No EVA
rs3408601832 686 P>H No EVA
rs3389497456 706 K>N No EVA
rs3407778185 720 A>E No EVA
rs3389505123 723 M>I No EVA
rs3389496174 729 L>M No EVA
rs3389497385 731 I>T No EVA
rs258500220 817 S>N No EVA
rs3389510757 818 H>Y No EVA
rs225339084 825 P>S No EVA
rs3389492780 860 G>D No EVA
rs3389491513 868 W>C No EVA
rs3389488566 901 G>* No EVA

No associated diseases with Q91Y11

2 regional properties for Q91Y11

Type Name Position InterPro Accession
domain Homeobox domain 67 - 128 IPR001356
domain TRAM/LAG1/CLN8 homology domain 131 - 332 IPR006634

Functions

Description
EC Number
Subcellular Localization
  • Cell membrane ; Single-pass type I membrane protein
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

2 GO annotations of cellular component

Name Definition
integral component of plasma membrane The component of the plasma membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane.
membrane A lipid bilayer along with all the proteins and protein complexes embedded in it an attached to it.

1 GO annotations of molecular function

Name Definition
calcium ion binding Binding to a calcium ion (Ca2+).

2 GO annotations of biological process

Name Definition
cell adhesion The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules.
homophilic cell adhesion via plasma membrane adhesion molecules The attachment of a plasma membrane adhesion molecule in one cell to an identical molecule in an adjacent cell.

6 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
Q5DRF2 PCDHA12 Protocadherin alpha-12 Pan troglodytes (Chimpanzee) PR
Q5DRF4 PCDHA10 Protocadherin alpha-10 Pan troglodytes (Chimpanzee) PR
Q9Y5I2 PCDHA10 Protocadherin alpha-10 Homo sapiens (Human) PR
Q9UN75 PCDHA12 Protocadherin alpha-12 Homo sapiens (Human) PR
Q8VHF2 Cdhr5 Cadherin-related family member 5 Mus musculus (Mouse) PR
O88689 Pcdha4 Protocadherin alpha-4 Mus musculus (Mouse) PR
10 20 30 40 50 60
MRLGNRPEDI RTCVHLRWHI HGLLRQENAS VVISKCLRHG AWRLLLWLLL LATWDVGSGQ
70 80 90 100 110 120
LHYSVPEEAK HGTFVGRIAQ DLGLELAELV PRLFRVVSKD RGDLLEVNLQ NGILFVNSRI
130 140 150 160 170 180
DREELCGQNA ECSIHLEVIV DRPLQVFHVE VEVRDINDNP PIFSVAEQKI LVAESRLLDS
190 200 210 220 230 240
RFPLEGASDA DVGENSMLTY KLSSNEFFIL DIVNKRGKGK FPVLVLRKLI DREENPQLKL
250 260 270 280 290 300
LLTATDGGKP EFTGSVSLLI QVLDVNDNAP VFDRSVYEVK MYENQENKTL VIWLNATDSD
310 320 330 340 350 360
EGINKEVEYS FSSLASSIIR QKFLINEKTG EIKINGAIDF EESNNYEIHV DATDKGYPPM
370 380 390 400 410 420
VAHCTVLVEI LDENDNAPEI VLTSLSLPVK EDAPLGSVIA LISVSDKDSG VNGQVTCSLT
430 440 450 460 470 480
NHVPFKLVST FKNYYSLVLD SALDRETTAD YKVVVTARDG GSPSLWATAS VSVEVADVND
490 500 510 520 530 540
NAPAFAHPEY TVFVKENNPP GVHIFTVLAV DADAQENALV SYSLVERRVG ERLLSSYVSV
550 560 570 580 590 600
HAESGKVFAL QPLDHEELEL LQFQVSARDA GVPALGSNVT LQVFVQDEND NPPTLLGHQS
610 620 630 640 650 660
GGPAGEFSQL VSRSVGAGHV VSKVRAVDAD SGYNAWLSYE LHPTVGARSP FRVGLYTGEI
670 680 690 700 710 720
SMTRALDESD LPRQRLLVLV KDHGEPMLIA TATVLVSLVE NGQVPKASSQ GLPNSSRREA
730 740 750 760 770 780
SLMDVNVYLI IAICAVSSLL VLTLLLYTAL RCSAVPMQAG CGLGKPTLVC SSAVGTWSYS
790 800 810 820 830 840
QQRQQRVCSG EGPPKTDLMA FSPSLTPCPV AEVGMESHSV GGDVPGKPRQ PNPDWRYSAS
850 860 870 880 890 900
LRAGMHSSVH LEEAGILRAG PGGPDQQWPT VSSATPEPEA GEVSPPVGAG VNSNSWTFKY
910 920 930 940 950 960
GPGNPKQSGP GELPDKFIIP GSPAIISIRQ EPANNQIDKS DFITFGKKEE TKKKKKKKKG
970
NKTQEKKEKG NSTTDNSDQ